Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Innovent/Lilly PD-1 Rejected by US FDA Panel; Lilly Says Price 40% Below Competition

publication date: Feb 10, 2022

As predicted, a US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody. Before the panel met, Lilly tried to influence the panel to approve the drug, sintilimab (Tyvyt), by announcing it would offer the drug at a wholesale price 40% lower than the US competition. The last-minute strategy didn't work: the panel voted 14-1 against approval. Yesterday, it seemed the main problem was the Phase III trial, which included only people with China genomes. But there were other issues as well. More details....

Stock Symbols: (HK: 01801) (NYSE: LLY) 

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital